[HER2 and gastric cancer: a novel therapeutic target for trastuzumab]
- PMID: 21134821
- DOI: 10.1684/bdc.2010.1224
[HER2 and gastric cancer: a novel therapeutic target for trastuzumab]
Abstract
HER2 protein overexpression by immunohistochemistry (IHC) and/or erB2 gene amplification by in situ hybridization (ISH) was detected in 4-28% of gastric or gastro-oesophageal junction (GOJ) cancers. Most studies have shown that HER2-overexpressing gastric cancers were worse prognosis. Trastuzumab is a humanized monoclonal antibody directed against HER2 with known efficacy in patients with HER2+ early or metastatic breast cancer. The international randomized trial ToGA study showed the superiority of the combination of trastuzumab with chemotherapy doublet fluoropyrimidine (5-FU or capecitabine) plus cisplatin (FP) every three weeks compared with chemotherapy alone in terms of overall survival : 13.8 versus 11.1 months (HR: 0.74, 95% CI: 0.60-0.91, P = 0.0046) in HER2+ advanced gastric cancers. The benefit was even greater in the subgroup with HER2 overexpression (16% of the screened population) as defined by IHC3+ or IHC2+ confirmed by positive ISH test. Trastuzumab plus FP chemotherapy has become the standard treatment for patients with HER2+ non-pretreated metastatic adenocarcinoma of the stomach or GOJ cancer. All these cancers should be tested for HER2 on paraffin block resection or biopsy specimens of the primary tumour or metastases. Endoscopic gastric biopsies should be multiple. The IHC should be the initial test. The standardized immunohistochemical scoring system differs from that recommended for breast cancer given the heterogeneity of HER2 expression and the frequency of incomplete membranous staining in gastric cancers. Equivocal IHC2+ tumours should be tested by ISH with two tools: fluorescence in situ hybridization (FISH) or bright field in situ hybridization (SISH). The perspectives are the assessment of trastuzumab in the perioperative and adjuvant setting, the development of novel anti-HER2 drugs and research into mechanisms of resistance and predictive molecular markers.
Similar articles
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.
-
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.Health Technol Assess. 2011 May;15 Suppl 1:33-42. doi: 10.3310/hta15suppl1/04. Health Technol Assess. 2011. PMID: 21609651 Review.
-
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):295-300. doi: 10.3760/cma.j.issn.0253-3766.2013.04.012. Zhonghua Zhong Liu Za Zhi. 2013. PMID: 23985260 Clinical Trial. Chinese.
-
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4. BMC Cancer. 2019. PMID: 31126258 Free PMC article. Clinical Trial.
-
Trastuzumab: in HER2-positive metastatic gastric cancer.Drugs. 2010 Dec 3;70(17):2259-67. doi: 10.2165/11205900-000000000-00000. Drugs. 2010. PMID: 21080742 Review.
Cited by
-
Amplification and clinicopathological significance of HER-2 in Kazakh esophageal squamous cell carcinoma.Mol Clin Oncol. 2020 Nov;13(5):64. doi: 10.3892/mco.2020.2134. Epub 2020 Sep 11. Mol Clin Oncol. 2020. PMID: 32968485 Free PMC article.
-
The principles of the surgical management of gastric cancer.Int J Surg Oncol (N Y). 2017 Aug;2(7):e11. doi: 10.1097/IJ9.0000000000000011. Epub 2017 Jul 12. Int J Surg Oncol (N Y). 2017. PMID: 29177225 Free PMC article.
-
KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?Gastroenterol Res Pract. 2015;2015:753903. doi: 10.1155/2015/753903. Epub 2015 Apr 23. Gastroenterol Res Pract. 2015. PMID: 25983749 Free PMC article.
-
PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.Anticancer Drugs. 2014 Nov;25(10):1129-40. doi: 10.1097/CAD.0000000000000148. Anticancer Drugs. 2014. PMID: 25035961 Free PMC article.
-
Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.World J Gastroenterol. 2013;19(14):2171-8. doi: 10.3748/wjg.v19.i14.2171. World J Gastroenterol. 2013. PMID: 23599643 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous